A Population-based Cohort Study of Pregnancy Outcomes Among Women With Primary Sclerosing Cholangitis

Ludvigsson, Jonas F.; Bergquist, Annika; Ajne, Gunilla; Kane, Sunanda V.; Ekbom, Anders; Stephansson, Olof

doi:10.1016/j.cgh.2013.07.011

Cited by 50 publications

(50 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The effect of pregnancy on the cholestatic autoimmune liver diseases PBC and PSC is milder, although liver enzymes may increase temporarily in both diseases in a considerable proportion of patients after delivery [206][207][208][209]. However, maternal and fetal outcome does not seem to be impaired in mothers with PBC and PSC.…”

Section: Clinical Relevancementioning

confidence: 89%

Immunology of hepatic diseases during pregnancy

2016

View full text Add to dashboard Cite

The mother's immune system has to adapt to pregnancy accepting the semi-allograft fetus and preventing harmful effects to the developing child. Aberrations in feto-maternal immune adaptation may result in disease of the mother, such as liver injury. Five pregnancy-associated liver disorders have been described so far, however, little is known concerning immune alterations promoting the respective disease. These liver disorders are pre-eclampsia, hemolysis, elevated liver enzymes, low platelet count (HELLP), acute fatty liver, hyperemesis gravidarum, and intrahepatic cholestasis of pregnancy. On the other hand, pre-existing autoimmune liver injury of the mother can be affected by pregnancy. This review intends to summarize current knowledge linking feto-maternal immunology and liver inflammation with a special emphasis on novel potential biomarkers.

show abstract

Section: Clinical Relevancementioning

confidence: 89%

Immunology of hepatic diseases during pregnancy

2016

View full text Add to dashboard Cite

show abstract

“…Reflecting the controversy, while the American guidelines do not recommend the use of UDCA as a prophylaxis agent against CRC (75) , the European guidelines suggest its use for high-risk patients (those with extensive colitis, positive family history or previous CRC), although it recognizes that there is limited evidence (68) . In general, fertility is not affected and pregnancy is well tolerated in individuals with well-controlled PSC (100)(101)(102) . The presence of PSC seems to be associated with the occurrence of preterm birth, with possible contribution of the presence of IBD activity (101,102) .…”

Section: Pharmacological Treatment Of Pscmentioning

confidence: 99%

“…In general, fertility is not affected and pregnancy is well tolerated in individuals with well-controlled PSC (100)(101)(102) . The presence of PSC seems to be associated with the occurrence of preterm birth, with possible contribution of the presence of IBD activity (101,102) . There is no increased risk of congenital malformations or other adverse pregnancy outcomes (101,102) .…”

Section: Pharmacological Treatment Of Pscmentioning

confidence: 99%

“…The presence of PSC seems to be associated with the occurrence of preterm birth, with possible contribution of the presence of IBD activity (101,102) . There is no increased risk of congenital malformations or other adverse pregnancy outcomes (101,102) . UDCA, qualified as a Class B drug by the FDA (Food and Drug Administration, USA), appears to be safe to be used in the second or third trimesters of pregnancy (101) .…”

Section: Pharmacological Treatment Of Pscmentioning

confidence: 99%

“…Even its early use during the first trimester has not been associated with negative effects on the mother or the fetus (101) . Exacerbation of PSC, worsening pruritus or de novo pruritus may occur during pregnancy or postpartum, requiring UDCA beginning or increasing dosage, and can lead to preterm birth (100)(101)(102)(103) . In one study, pregnant women on UDCA most frequently had stable liver tests, compared to those who did not use the drug (101) .…”

Section: Pharmacological Treatment Of Pscmentioning

confidence: 99%

See 2 more Smart Citations

Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver

Bittencourt

Cançado

Couto

et al. 2015

Arq. Gastroenterol.

View full text Add to dashboard Cite

-In order to draw evidence-based recommendations concerning the management of autoimmune diseases of the liver, the Brazilian Society of Hepatology has sponsored a single-topic meeting in October 18th, 2014 at São Paulo. An organizing committee comprised of seven investigators was previously elected by the Governing Board to organize the scientific agenda as well as to select twenty panelists to make a systematic review of the literature and to present topics related to the diagnosis and treatment of autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cirrhosis and their overlap syndromes. After the meeting, all panelists gathered together for the discussion of the topics and the elaboration of those recommendations. The text was subsequently submitted for suggestions and approval of all members of the Brazilian Society of Hepatology through its homepage. The present paper is the final version of the reviewed manuscript organized in topics, followed by the recommendations of the Brazilian Society of Hepatology.

show abstract

Pregnancy and Liver Disease

King

Westbrook

2019

Evidence‐based Gastroenterology and Hepatology 4e

View full text Add to dashboard Cite

A Population-based Cohort Study of Pregnancy Outcomes Among Women With Primary Sclerosing Cholangitis

Cited by 50 publications

References 18 publications

Immunology of hepatic diseases during pregnancy

Immunology of hepatic diseases during pregnancy

Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver

Pregnancy and Liver Disease

Contact Info

Product

Resources

About